Kirsten L. Bryant

University of North Carolina at Chapel Hill — United States

Medicine · Health Sciences

20h-index3.5kcitations198works2.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pancreatic and Hepatic Oncology Research(93), Advanced Breast Cancer Therapies(59), Colorectal Cancer Treatments and Studies(37), Cancer, Hypoxia, and Metabolism(27), Autophagy in Disease and Therapy(24)

Publications198 total

Dordaviprone/ONC201 Activation of the ClpP Mitochondrial Protease Inhibits the Growth of KRAS-Mutant Pancreatic Cancer and Overcomes RAS Inhibitor Resistance
2025Open Access
Figure S3 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
2025Open Access
Figure S7 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
2025Open Access
Figure S2 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
2025Open Access
Figure S1 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
2025Open Access
Figure S4 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
2025Open Access
Figure S6 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
2025Open Access
Figure S5 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
2025Open Access
Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
2025Open Access
Figure S7 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
2025Open Access
Figure S2 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
2025Open Access
Figure S2 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
2025Open Access
Figure S5 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
2025Open Access
Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
2025Open Access
Supplementary Data and Materials from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
2025Open Access
Figure S1 page4 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
2025Open Access
Figure S1 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
2025Open Access
Figure S6 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
2025Open Access
Supplementary Tables from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
2025Open Access
Figure S1 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
2025Open Access
page 1 of 10Next →

Frequent Co-authors

Channing J. Der(38), Adrienne D. Cox(28), Mariaelena Pierobon(21), Clint A. Stalnecker(19), Jennifer E. Klomp(15), Craig M. Goodwin(15), Andrew M. Waters(14), Bjoern Papke(14), Kristina Drizyte‐Miller(12), Elisa Baldelli(12), Emanuel F. Petricoin(11), Prson Gautam(10), Krister Wennerberg(10), Emanuel F. Petricoin(10), Runying Yang(9), Jonathan M. DeLiberty(8), J. Nathaniel Diehl(7), Jeffrey A. Klomp(7), Wen-Hsuan Chang(7), Sen Peng(6)